119 related articles for article (PubMed ID: 30192155)
1. Costs associated with adverse events for systemic therapies in metastatic melanoma.
Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
[TBL] [Abstract][Full Text] [Related]
2. Economic burden associated with adverse events in patients with metastatic melanoma.
Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
[TBL] [Abstract][Full Text] [Related]
3. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
4. Comparative healthcare costs in patients with metastatic melanoma in the USA.
Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review.
Gorry C; McCullagh L; Barry M
Value Health; 2020 Jan; 23(1):52-60. PubMed ID: 31952674
[TBL] [Abstract][Full Text] [Related]
6. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
7. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
Ghate SR; Li Z; Tang J; Nakasato AR
Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
[TBL] [Abstract][Full Text] [Related]
8. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
10. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
11. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
12. Accounting for Cured Patients in Cost-Effectiveness Analysis.
Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
[TBL] [Abstract][Full Text] [Related]
14. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
[TBL] [Abstract][Full Text] [Related]
15. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
16. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
Borker R
J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
[TBL] [Abstract][Full Text] [Related]
18. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
[TBL] [Abstract][Full Text] [Related]
19. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Franken MG; Leeneman B; Jochems A; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; van der Hoeven KJM; Hospers GAP; Kapiteijn E; Koornstra R; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van Zeijl M; Haanen JBAG; Uyl-de Groot CA
Anticancer Drugs; 2018 Jul; 29(6):579-588. PubMed ID: 29634490
[TBL] [Abstract][Full Text] [Related]
20. Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.
Ma Q; Zhao Z; Barber BL; Shilkrut M
Adv Ther; 2016 Feb; 33(2):282-9. PubMed ID: 26797898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
